CLINICAL SIGNIFICANCE OF INCREASED SERUM NEOPTERIN IN CHRONIC KIDNEY FAILURE AS A BIOMARKER OF CELL-MEDIATED IMMUNITY

Basit Öğe Kaydı
dc.authoridÜnüvar, Songül/0000-0001-8454-490X
dc.authorwosidÜnüvar, Songül/ABH-5516-2020
dc.contributor.authorUnuvar, Songul
dc.contributor.authorAslanhan, Hamza
dc.date.accessioned2024-08-04T20:44:37Z
dc.date.available2024-08-04T20:44:37Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Neopterin is a pyrazino-pyrimidine compound which is used as a marker of cell-mediated immunity in a variety of diseases. It is known that neopterin levels increase in diseases where interferon-gamma (IFN-gamma) stimulation is present, and also as a result of deficiencies in renal function, given that the primary means of elimination of neopterin is through the kidneys. In this study, we aimed to investigate the role of increased neopterin levels as a prognostic biomarker in patients with impaired renal function. Methods: A total of 90 individuals including 63 patients with chronic kidney failure (CKF) and 27 healthy volunteers were included in the study. Serum neopterin concentrations were measured using the enzyme-linked immunosorbent assay. A Mann-Whitney U test and a Pearson Correlation Test were used in the statistical analysis, with a p value of <0.05 being considered statistically significant. Results: The mean age was 52.21 +/- 0.16 years in the patient group and 56.55 +/- 0.32 years in the control group. In the CKF patients, serum neopterin levels increased to a significantly greater degree than in the control group (p<0.001), while no statistically significant correlation was identified between serum neopterin levels and age (p>0.05). Conclusions: A significant increase was found in the serum neopterin levels in the CKF patients, due to both the triggering of the disease and the reduction of neopterin elimination.en_US
dc.identifier.doi10.2478/jomb-2018-0019
dc.identifier.endpage5en_US
dc.identifier.issn1452-8258
dc.identifier.issn1452-8266
dc.identifier.issue1en_US
dc.identifier.pmid30820177en_US
dc.identifier.scopus2-s2.0-85049224814en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.2478/jomb-2018-0019
dc.identifier.urihttps://hdl.handle.net/11616/98364
dc.identifier.volume38en_US
dc.identifier.wosWOS:000451080000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSciendoen_US
dc.relation.ispartofJournal of Medical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcell-mediated immunityen_US
dc.subjectchronic kidney failureen_US
dc.subjectneopterinen_US
dc.subjectrenal diseasesen_US
dc.titleCLINICAL SIGNIFICANCE OF INCREASED SERUM NEOPTERIN IN CHRONIC KIDNEY FAILURE AS A BIOMARKER OF CELL-MEDIATED IMMUNITYen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu